SynthesisCancer letters2016
Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review.
Synthesis in Cancer letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 70 citations in OpenAlex.
- RNAi-based therapeutics targeting the F gene in human metapneumovirus: An in-silico approach.Journal, genetic engineering & biotechnology · 2026Article
- Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.Open forum infectious diseases · 2026Article
- Review
- The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review.Infectious diseases and therapy · 2025Article
- Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.American journal of hematology · 2025Article
- Prognosis of critically ill immunocompromised patients with virus-detected acute respiratory failure.Annals of intensive care · 2023Article
- Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: Lessons learned.American journal of infection control · 2023Article
- Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults.Open forum infectious diseases · 2022Article
- Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.GMS hygiene and infection control · 2022Article
- Review
- Article
- Antibody recognition of the Pneumovirus fusion protein trimer interface.PLoS pathogens · 2020Article
- Viral Respiratory Infections in Hematological Patients.Infectious diseases and therapy · 2020Review
- HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients.Pathogens (Basel, Switzerland) · 2020Review
- Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections.Haematologica · 2020Article
- Possible role of highly activated mucosal NK cells against viral respiratory infections in children undergoing haematopoietic stem cell transplantation.Scientific reports · 2019Article
- Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients?Microorganisms · 2019Review
- A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human MetapneumovirusJournal of virology · 2019Article
- Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs.Clinical microbiology reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Over the past decade, reported incidence of human metapneumovirus (hMPV) has increased owing to the use of molecular assays for diagnosis of respiratory viral infections in cancer patients. The seasonality of these infections, differences in sampling strategies across institutions, and small sample size of published studies make it difficult to appreciate the true incidence and impact of hMPV infections. In this systematic review, we summarized the published data on hMPV infections in hematopoietic cell transplant recipients and patients with hematologic malignancy, focusing on incidence, hMPV-associated lower respiratory tract infection (LRTI), mortality, prevention, and management with ribavirin and/or intravenous immunoglobulins. Although the incidence of hMPV infections and hMPV-associated LRTI in this patient population is similar to respiratory syncytial virus or parainfluenza virus and despite lack of directed antiviral therapy, the mortality rate remains low unless patients develop LRTI. In the absence of vaccine to prevent hMPV, infection control measures are recommended to reduce its burden in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.